Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Clinics in Indiana

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What Indiana law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and listings with their verification status.

Indiana at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Clinics serving Indiana

No verified clinics serving Indiana are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Indiana

Yes. An Indiana resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Indiana-licensed prescriber, including by telehealth under Indiana Code 25-1-9.5, which lets a prescriber issue a prescription to a telehealth patient the prescriber has not examined in person if the standard of care is met. Under that chapter, an Internet questionnaire with a new patient does not count as telehealth. Compounded peptides are available when eligible under federal 503A rules and dispensed by an Indiana pharmacy or a nonresident pharmacy licensed by the Indiana Board of Pharmacy. Indiana tightened compounding in 2026: Senate Enrolled Act 282, signed March 5, 2026, requires bulk drug substances used in compounding to come from FDA-registered manufacturers with a certificate of analysis and requires medical spas to register with the Medical Licensing Board beginning January 1, 2027. [1] [2] [3] [4] [5] [6] [7]

Compounded GLP-1 access in Indiana

Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Indiana's 2026 law adds sourcing rules (FDA-registered bulk manufacturers with certificates of analysis) that exclude the unregistered active ingredient suppliers behind many cheap compounded GLP-1 products. Medical spas offering GLP-1 injections will need to register with the Medical Licensing Board from January 1, 2027. [5] [10]

Research use only sellers in Indiana

Only Indiana-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Indiana patients, and Senate Enrolled Act 282 (2026) requires compounders to source bulk substances from FDA-registered establishments. Indiana Code 16-42-22.5, added by that act, expressly bars compounding with a research grade bulk substance outside an IRB-approved study. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and do not meet Indiana's new sourcing standard. [3] [5] [6] [11]

Indiana notes on specific peptides

  • Semaglutide: Available branded by prescription, including by telehealth under Indiana Code 25-1-9.5. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025, and Indiana compounders must now use FDA-registered bulk sources with a certificate of analysis. [2] [5] [10]
  • BPC-157: Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Indiana's 2026 law also requires the bulk substance to come from an FDA-registered establishment with a certificate of analysis. [5] [8] [9] [12] [13]

How to check a clinic in Indiana

  1. Confirm the prescribing clinician's license with the Indiana medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Indiana Board of Pharmacy (Indiana Professional Licensing Agency) license lookup. [1] [3] [4] [5] [6] [7]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Indiana. [3] [5] [6] [11]

Sources

  1. [1]Indiana Board of Pharmacy, Indiana Professional Licensing Agency
  2. [2]Indiana Code 25-1-9.5, Telehealth services and prescriptions (Indiana General Assembly, 2026 Indiana Code)
  3. [3]Senate Enrolled Act 282 (2026), enrolled text, Public Law 136, adding Indiana Code 16-42-22.5
  4. [4]856 Indiana Administrative Code Article 1, Pharmacies and Pharmacists (including Rule 30, sterile pharmaceuticals)
  5. [5]Indiana General Assembly, Senate Bill 282 (2026), Compounding drugs; registration of medical spas
  6. [6]Indiana Code Title 25, Article 26, Chapter 17, Nonresident pharmacies
  7. [7]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  9. [9]FDA: Pharmacy Compounding Advisory CommitteeFDA
  10. [10]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA